Verlukast (CAS 120443-16-5)
QUICK LINKS
A receptor antagonist targeting the study of respiratory diseases functions by selectively inhibiting receptors that play a role in the development and progression of these conditions. This selective blockade interferes with the pathological signaling pathways that contribute to respiratory symptoms and disease mechanisms, such as inflammation, airway constriction, and excessive mucus production. The modulation of inflammatory responses, which are often central to the disease′s progression, the reduction of airway constriction that characterizes many respiratory conditions, and the curtailment of excessive mucus production, a common symptom that exacerbates patient discomfort and disease severity. The ability of this antagonist to precisely navigate and interfere with these complex biological networks not only sheds light on the intricate mechanisms at play in respiratory diseases but also paves the way for exploring novel research avenues and understanding the molecular intricacies involved in disease pathogenesis and progression.
Verlukast (CAS 120443-16-5) References
- Priming of alveolar macrophages by leukotriene D(4): potentiation of inflammation. | Ménard, G. and Bissonnette, EY. 2000. Am J Respir Cell Mol Biol. 23: 572-7. PMID: 11017925
- In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. | Fang, J., et al. 2001. Drug Metab Dispos. 29: 1638-43. PMID: 11717183
- In vitro and in vivo biotransformations of the potent leukotriene D4 antagonist verlukast in the rat. | Nicoll-Griffith, D., et al. 1992. Drug Metab Dispos. 20: 383-9. PMID: 1355712
- Assessing the issue of instability due to Michael adduct formation in novel chemical entities possessing a carbon-carbon double bond during early drug development--applicability of common laboratory analytical protocols. | Polepally, AR., et al. 2008. Biomed Chromatogr. 22: 960-76. PMID: 18683847
- A curated binary pattern multitarget dataset of focused ATP-binding cassette transporter inhibitors. | Stefan, SM., et al. 2022. Sci Data. 9: 446. PMID: 35882865
- Robotic sample preparation and high-performance liquid chromatographic analysis of verlukast in human plasma. | Hsieh, JY., et al. 1994. J Chromatogr B Biomed Appl. 661: 307-12. PMID: 7894671
- CYP1A1 specificity of Verlukast epoxidation in mice, rats, rhesus monkeys, and humans. | Grossman, SJ., et al. 1993. Drug Metab Dispos. 21: 1029-36. PMID: 7905381
- Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile. | Nicoll-Griffith, DA., et al. 1995. Drug Metab Dispos. 23: 1085-93. PMID: 8654196
- Screening and selection of a microbial lipase for the stereospecific hydrolysis of Verlukast | L. Katz, C. Marcin, L. Zitano, J. King, K. Price, N. Grinberg, M. Bhupathy, J. McNamara, J. Bergan, R. Greasham & M. Chartrain. 1993. Journal of Industrial Microbiology. 11: 89–94.
- Purification and characterization of a novel bioconverting lipase from Pseudomonas aeruginosa MB 5001 | M Chartrain, L Katz, C Marcin, M Thien, S Smith. 1993. Enzyme and Microbial Technology. 15, 7: 575-580.
- Evolution of a series of non-quinoline leukotriene D4 receptor antagonist; synthesis and sar of benzothiazoles and thiazoles substituted benzyl alcohols as potent LTD4 antagonists | CK Lau, C Dufresne, Y Gareau, R Zamboni. 1995. Bioorganic & Medicinal Chemistry Letters. 5, 15: 1615-1620.
- The discovery of CP-96,021 and CP-96,486, balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonists. | A Marfat, R Chambers, J Cheng, K Cooper. 1995. Bioorganic & Medicinal Chemistry Letters. 5, 13: 1377-1382.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Verlukast, 10 mg | sc-213152 | 10 mg | $453.00 |